Search

Your search keyword '"Bettencourt A"' showing total 695 results

Search Constraints

Start Over You searched for: Author "Bettencourt A" Remove constraint Author: "Bettencourt A" Topic female Remove constraint Topic: female
695 results on '"Bettencourt A"'

Search Results

1. Combination of computed tomography angiography with coronary artery calcium score for improved diagnosis of coronary artery disease: a collaborative meta-analysis of stable chest pain patients referred for invasive coronary angiography.

2. MEFIB‐Index and MAST‐Score in the assessment of hepatic decompensation in metabolic dysfunction‐associated steatosis liver disease—Individual participant data meta‐analyses

3. Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial

4. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis

5. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes

6. Prevalence and factors associated with liver fibrosis among first‐degree relatives of Mexican Americans with hepatocellular carcinoma

7. Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.

8. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)

9. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study

10. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis

11. The impact of genetic risk on liver fibrosis in non‐alcoholic fatty liver disease as assessed by magnetic resonance elastography

12. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard

13. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis

14. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease

15. MRI Assessment of Treatment Response in HIV‐associated NAFLD: A Randomized Trial of a Stearoyl‐Coenzyme‐A‐Desaturase‐1 Inhibitor (ARRIVE Trial)

16. Do effects of early life interventions on linear growth correspond to effects on neurobehavioural development? A systematic review and meta-analysis

17. Collagen Formation Assessed by N‐Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography

18. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.

19. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants

20. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose‐dependent changes with increase in fibrosis stage in patients with biopsy‐proven NAFLD

21. Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease

22. Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD

23. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

24. Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

25. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study

26. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

27. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

28. Smartphone-Based Geofencing to Ascertain Hospitalizations

29. Assessment of treatment response in non‐alcoholic steatohepatitis using advanced magnetic resonance imaging

30. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease

31. Novel candidate blood‐based transcriptional biomarkers of machado‐joseph disease

32. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.

33. Association of Nonalcoholic Fatty Liver Disease With Visceral Adiposity but Not Coronary Artery Calcification in the Elderly

34. Magnetic resonance elastography identifies fibrosis in adults with alpha‐1 antitrypsin deficiency liver disease: a prospective study

35. Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE

36. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study.

37. Novel association between serum pentraxin‐2 levels and advanced fibrosis in well‐characterised patients with non‐alcoholic fatty liver disease

38. Perceptions, Information Sources, and Behavior Regarding Alcohol and Heart Health

39. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis

40. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

41. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY)

42. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials

43. Feed intake, milk production and metabolism of Holstein, Gyr and Girolando-F1 heifers with high body condition score during the transition period

44. Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD

45. Comparative efficacy of an optimal exam between ultrasound versus abbreviated <scp>MRI</scp> for <scp>HCC</scp> screening in <scp>NAFLD</scp> cirrhosis: A prospective study

46. Outcomes of primary total hip arthroplasty following septic arthritis of the hip

47. Genetic defects are common in myopathies with tubular aggregates

48. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

49. Glucose variability predicts 6-month mortality in patients hospitalized with acute heart failure

50. Identification of multiple system atrophy mimicking Parkinson’s disease or progressive supranuclear palsy

Catalog

Books, media, physical & digital resources